(Q37241709)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24128713%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24128713%20AND%20SRC:MED&resulttype=core&format=json

squamous cell carcinoma of the lung

27 February 2020

main subject

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

dasatinib monohydrate

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24128713%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Andrew M Brunner

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24128713%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Rebecca S Heist

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24128713%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Elizabeth Garcia

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24128713%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Neal I Lindeman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24128713%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Lynette M Sholl

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24128713%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Geoffrey R Oxnard

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24128713%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Bruce E Johnson

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24128713%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Peter S Hammerman

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24128713%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

publication date

1 November 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24128713%20AND%20SRC:MED&resulttype=core&format=json

Journal of Thoracic Oncology

27 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24128713%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24128713%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24128713%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

1434-1437

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24128713%20AND%20SRC:MED&resulttype=core&format=json

Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib

27 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3801424

Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3801424

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3801424

Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3801424

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3801424

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3801424

Phase II study of dasatinib in patients with advanced non-small-cell lung cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3801424

Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3801424

A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3801424

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3801424

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3801424

Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3801424

Somatic mutations of the protein kinase gene family in human lung cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3801424

Planned versus attained design in phase II clinical trials

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3801424

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3801424

10.1097/JTO.0B013E3182A47162

3 September 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24128713%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24128713%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference